ZA201904185B - Tianeptine oxalate salts and polymorphs - Google Patents

Tianeptine oxalate salts and polymorphs

Info

Publication number
ZA201904185B
ZA201904185B ZA2019/04185A ZA201904185A ZA201904185B ZA 201904185 B ZA201904185 B ZA 201904185B ZA 2019/04185 A ZA2019/04185 A ZA 2019/04185A ZA 201904185 A ZA201904185 A ZA 201904185A ZA 201904185 B ZA201904185 B ZA 201904185B
Authority
ZA
South Africa
Prior art keywords
polymorphs
oxalate salts
tianeptine oxalate
tianeptine
salts
Prior art date
Application number
ZA2019/04185A
Other languages
English (en)
Inventor
Luca Giaffreda Stefano
Modena Enrico
Fabbroni Serena
Chiarucci Michel
T Edgar Mark
Original Assignee
Tonix Pharma Holdings Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tonix Pharma Holdings Ltd filed Critical Tonix Pharma Holdings Ltd
Publication of ZA201904185B publication Critical patent/ZA201904185B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D281/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one sulfur atom as the only ring hetero atoms
    • C07D281/02—Seven-membered rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Medicinal Preparation (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
ZA2019/04185A 2016-12-28 2019-06-26 Tianeptine oxalate salts and polymorphs ZA201904185B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662439533P 2016-12-28 2016-12-28
PCT/IB2017/001709 WO2018122606A1 (en) 2016-12-28 2017-12-28 Tianeptine oxalate salts and polymorphs

Publications (1)

Publication Number Publication Date
ZA201904185B true ZA201904185B (en) 2021-10-27

Family

ID=61283255

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA2019/04185A ZA201904185B (en) 2016-12-28 2019-06-26 Tianeptine oxalate salts and polymorphs

Country Status (13)

Country Link
US (2) US10449203B2 (enExample)
EP (1) EP3562812A1 (enExample)
JP (2) JP2020503330A (enExample)
CN (1) CN110418785A (enExample)
AU (1) AU2017385958B2 (enExample)
BR (1) BR112019013244A2 (enExample)
CA (1) CA3048324A1 (enExample)
IL (1) IL267708A (enExample)
MX (1) MX2019007891A (enExample)
MY (1) MY199385A (enExample)
NZ (1) NZ754797A (enExample)
WO (1) WO2018122606A1 (enExample)
ZA (1) ZA201904185B (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ754797A (en) * 2016-12-28 2022-05-27 Tonix Pharma Holdings Ltd Tianeptine oxalate salts and polymorphs
US20240165126A1 (en) 2021-03-15 2024-05-23 Tonix Pharmaceuticals Holding Corp. Tianeptine oxalate and naloxone combination for the treatment of major depressive disorder
CN117769540A (zh) * 2021-05-11 2024-03-26 亚士德制药公司 4-[5-[(3S)-3-氨基吡咯烷-l-羰基]-2-[2-氟-4-(2-羟基-2-乙基丙基)苯基]苯基]-2-氟-苯甲腈的盐的固体形式

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3758528A (en) * 1970-03-13 1973-09-11 Science Union & Cie Tricyclic compounds
FR2635461B1 (fr) * 1988-08-18 1992-01-17 Adir Utilisation de derives tricycliques pour l'obtention de medicaments destines au traitement du stress
US5405842A (en) 1994-01-28 1995-04-11 Silverman; Bernard A. Treatment of steroid dependent asthmatics
FR2791891A1 (fr) 1999-04-07 2000-10-13 Adir Utilisation de la tianeptine pour l'obtention de medicaments destines au traitement des pathologies de la neurodegenerescence
TW200517114A (en) 2003-10-15 2005-06-01 Combinatorx Inc Methods and reagents for the treatment of immunoinflammatory disorders
US9314469B2 (en) 2008-05-05 2016-04-19 Tonix Pharma Holdings Limited Method for treating neurocognitive dysfunction
US8198268B2 (en) * 2008-10-31 2012-06-12 Janssen Biotech, Inc. Tianeptine sulfate salt forms and methods of making and using the same
NZ754797A (en) * 2016-12-28 2022-05-27 Tonix Pharma Holdings Ltd Tianeptine oxalate salts and polymorphs

Also Published As

Publication number Publication date
US10449203B2 (en) 2019-10-22
AU2017385958B2 (en) 2021-12-02
CN110418785A (zh) 2019-11-05
MY199385A (en) 2023-10-25
US10946027B2 (en) 2021-03-16
WO2018122606A1 (en) 2018-07-05
US20200276208A1 (en) 2020-09-03
JP2023001340A (ja) 2023-01-04
NZ754797A (en) 2022-05-27
EP3562812A1 (en) 2019-11-06
AU2017385958A1 (en) 2019-07-11
IL267708A (en) 2019-08-29
US20180338984A1 (en) 2018-11-29
MX2019007891A (es) 2019-12-16
CA3048324A1 (en) 2018-07-05
JP2020503330A (ja) 2020-01-30
BR112019013244A2 (pt) 2019-12-24

Similar Documents

Publication Publication Date Title
IL284874A (en) Valbenazine salts and polymorphs thereof
SG11201607586UA (en) Fused pyrimidine-based hydroxamate derivatives
GB201609405D0 (en) Head support
IL267529A (en) polymorphs
ZA201903936B (en) Polymorphs
IL256985A (en) Compounds for inducing tissue formation and their uses
IL256980A (en) Compounds for inducing tissue formation and their uses
SG10202008598RA (en) Toothbrush
SI3247711T1 (sl) Nove soli in polimorfi SCY-078
HUP1600030A2 (en) Baricitinib salts
PL3189045T3 (pl) Nowe sole nilotynibu i jego polimorfy
IL267708A (en) Oxalate salts of tianeptine and polymorphs thereof, preparations containing them and their uses
GB2534220B (en) Tree-cutting head
GB2559848B (en) Towel Rail
HK40016627A (en) Tianeptine oxalate salts and polymorphs
IL286670A (en) Compounds for inducing tissue formation and their uses
HK1260336A1 (en) Valbenazine salts and polymorphs thereof
IL256968A (en) Compounds for inducing tissue formation and uses thereof
AU201616160S (en) Head Support
GB201608262D0 (en) Therapeutic salts